Cerebrovascular Complications and Polycythaemia Vera
- 81 Downloads
Polycythaemia vera (PV) is a stem cell-derived myeloid haematologic malignancy. It is characterized by an expansion of one or more haematopoietic cell lineages, resulting in increased mature blood components in the peripheral blood. The disease features include erythrocytosis, leukocytosis and/or thrombocytosis, as a consequence of which PV may exhibit a unique prothrombic state [1, 2]. There is a possibility of progression into acute myeloid leukaemia or myelofibrosis, the 10-year risk ranging between 3% and 10%, but the life expectancy of patients with PV is commonly affected by thrombo-haemorrhagic events, with a reported incidence of 12–39% [1, 3]. The clinical manifestations of the thrombotic events in PV patients may vary from mild microvascular circulatory disturbances (e.g. erythromelalgia, tinnitus or vertigo) to more severe complications, such as migraine-like cerebral transient ischaemic attacks, transient ischaemic attacks, ischaemic stroke, myocardial...
The authors express their thanks to the Institute of Medical Genetics, University of Szeged and to the Institute of Laboratory Medicine, University of Szeged for diagnostic tests.
Compliance with Ethical Standards
Conflicts of Interest
- 1.Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012:571–581. https://doi.org/10.1182/asheducation-2012.1.571 2012/1/571 Google Scholar
- 2.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
- 5.Sanahuja J, Marti-Fabregas J, Marti-Vilalta JL (2005) Carotid thrombus and cerebral infarction as the initial clinical manifestation of polycythemia vera. Neurologia 20(4):194–196Google Scholar
- 7.Abdel-Rahman I, Murphy C (2015, 2015) Recurrent ischaemic stroke unveils polycythaemia vera. BMJ Case Rep. https://doi.org/10.1136/bcr-2014-207625
- 8.Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome P (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061. https://doi.org/10.1016/S0140-6736(05)71142-9 CrossRefGoogle Scholar
- 10.Vokó Z, Széles G, Kardos L, Németh R, Ádány R (2008) The epidemiology of cerebrovascular diseases in Hungary after the millennium. LAM ( Lege Artis Medicinae) 18(1):31–38Google Scholar
- 12.Santisakultarm TP, Paduano CQ, Stokol T, Southard TL, Nishimura N, Skoda RC, Olbricht WL, Schafer AI, Silver RT, Schaffer CB (2014) Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. https://doi.org/10.1111/jth.1273